Bifidobacterium infantis

Bifidobacterium longum subsp. infantis BB-02

BB-02 (Chr. Hansen)

Helping protect very preterm infants from necrotizing enterocolitis when used with other strains.

Moderate Evidence12+ indexed studies

Quick Overview

At a Glance

Researched Benefits

  • Specifically studied for the NICU environment — one of the few probiotic strains with real-world data in premature infant care
  • Stable in human milk and common enteral feeding solutions for up to 4 hours, making safe preparation straightforward for hospital staff
  • Works as part of a proven multi-strain blend (with BB-12 and TH-4), providing more comprehensive early-life gut support than any single strain alone
  • May help reduce the risk of necrotizing enterocolitis (NEC) and late-onset sepsis — two of the most feared complications in very preterm infants

Usage & Application

Clinically Studied Dosage

1–3 Billion CFU/day (as part of a multi-strain blend, administered enterally)

Available Forms

Powder sachet (for enteral/tube feeding)Multi-strain powder blend (combined with BB-12 and TH-4)

Clinical Evidence

Necrotizing Enterocolitis Risk Reduction in Preterm Infants: Bifidobacterium longum infantis BB-02

BB-02 is a strain of Bifidobacterium longum subsp. infantis — a type of friendly bacteria that naturally colonizes the intestines of breastfed newborns. In healthy, full-term babies, this species is one of the very first microbes to move in and set up shop after birth, helping to train the immune system and protect the gut wall. But for babies born too early, that natural colonization process goes off-script. The NICU environment, the frequent need for antibiotics, and the delay in receiving breast milk can leave the preterm gut alarmingly empty of these protective bacteria. BB-02 was developed to step in and fill that gap. Think of it like sending in a construction crew to a building site that's behind schedule — it helps lay the foundation for a healthy gut microbiome when the baby's own biology can't do it fast enough.

The most important potential benefit of BB-02 in preterm infants is its role in supporting protection against necrotizing enterocolitis (NEC) — a devastating gut condition that is one of the leading causes of death in premature babies. NEC happens when the gut lining, which is still paper-thin and fragile in preterm infants, becomes overwhelmed by harmful bacteria and begins to break down. Friendly bacteria like BB-02 help by crowding out those dangerous microbes and reinforcing the gut's natural defenses. BB-02 is typically used as part of a carefully formulated three-strain blend alongside Bifidobacterium lactis (BB-12) and Streptococcus thermophilus (TH-4), a combination that has been studied specifically for use in the NICU setting. Research has shown that this multi-strain approach may meaningfully reduce the risk of NEC and late-onset sepsis — a serious bloodstream infection — in very low birth weight infants. Families of premature babies and the neonatologists caring for them are increasingly recognizing probiotics like BB-02 as a practical, low-risk tool in the NICU toolkit.

One of the most reassuring things about BB-02 is the practical research behind how it's actually given in the hospital. Studies have confirmed that when the three-strain blend containing BB-02 is mixed with common NICU feeding media — including human milk, preterm formula, sterile water, and saline — it remains stable and fully viable for up to four hours. That means pharmacy staff and nurses can prepare it safely in advance, and it can be delivered through standard feeding tubes without any loss of effectiveness. From a safety standpoint, BB-02 has a strong track record: it is considered safe for use in clinical NICU settings and is generally well tolerated even in extremely fragile, preterm infants. It is not intended for home use or for healthy, full-term babies — this is a strain designed for a very specific and high-stakes medical context. Parents and caregivers should always follow the guidance of their neonatology team when it comes to probiotic supplementation in the NICU.


Common Questions

Frequently Asked Questions


Sources

Scientific References

Curated By

Clara Hayes

Clara Hayes

Lead Research Editor

Clara leads the curation and verification of microbiome research for our platform. With extensive experience in translating complex scientific literature into accessible insights, she ensures every strain profile is grounded in peer-reviewed evidence and contextual accuracy.

!

Medical Disclaimer

The information provided on probioticstrains.com is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Strain profiles and clinical summaries are compiled from published peer-reviewed literature. While we may evaluate or highlight specific commercial formulations, our insights are always grounded in available scientific evidence. Always consult a qualified healthcare provider before starting, changing, or stopping any supplement or health regimen.